US · SCLX
Scilex Holding Company
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Palo Alto, CA 94303
- Website
- scilexholding.com
Price · as of 2024-12-31
$10.58
Market cap 70.13M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $400.30 | +3,683.55% |
| Intrinsic Value(DCF) | $4.86 | -54.06% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $347.20 | ||||
| 2021 | $354.90 | $166.07 | $173.69 | $0.00 | $0.00 |
| 2022 | $254.45 | $168.05 | $3.16 | $0.00 | $0.00 |
| 2023 | $49.70 | $61.33 | $0.14 | $0.00 | $0.00 |
| 2024 | $12.15 | $400.30 | $0.31 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Scilex Holding Company's (SCLX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $400.30
- Current price
- $10.58
- AI upside
- +3,683.55%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$4.86
-54.06% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SCLX | Scilex Holding Company | $10.58 | 70.13M | +3,684% | -54% | — | — | -1.16 | -0.44 | 1.49 | -1.78 | — | -0.35 | 70.51% | -147.37% | -128.66% | 39.83% | 80.83% | -74.96% | -0.20 | -42.48 | 0.16 | 0.11 | -0.52 | -5668.00% | 2107.00% | -19198.00% | 22.92% | 0.07 | -18.75% | 0.00% | 0.00% | 106.43% | -1.43 | 6.16 | 2.10 | -13.47 |
| ABOS | Acumen Pharmaceuticals, I… | $3.14 | 190.2M | — | — | — | — | -0.73 | 0.41 | — | 0.68 | -1.26 | 0.41 | 0.00% | — | — | -45.60% | -248.14% | -37.27% | 0.16 | -28.03 | 6.46 | 6.21 | 0.06 | 5833.00% | — | 10014.00% | -114.95% | -3.12 | -187.66% | 0.00% | 0.00% | 0.05% | 0.59 | 0.78 | — | -1.94 |
| AGEN | Agenus Inc. | $3.33 | 113.25M | +151% | -72% | — | +7,590% | -0.22 | -0.15 | 0.49 | -1.04 | — | -0.14 | -50.79% | -116.44% | -219.61% | 95.45% | 58.03% | -86.00% | -0.29 | -1.02 | 0.21 | 0.18 | -0.54 | -2298.00% | -3381.00% | -3214.00% | -314.88% | -0.72 | 76.54% | 0.00% | 0.00% | 0.00% | -0.87 | -0.66 | 1.01 | -15.68 |
| ALEC | Alector, Inc. | $2.43 | 265.24M | +1,084% | -64% | — | +3,751% | -1.59 | 7.43 | 10.82 | -0.06 | -12.24 | 7.43 | 54.09% | -692.83% | -679.16% | -181.56% | 67.31% | -37.54% | 1.18 | — | 3.83 | 3.68 | 0.22 | 1301.00% | -7907.00% | -2037.00% | -80.87% | -2.65 | 84.98% | 0.00% | 0.00% | 17.16% | -0.05 | -0.04 | 0.37 | -4.88 |
| CTOR | Citius Oncology, Inc. | $1.12 | 98.87M | — | — | — | — | -3.31 | 1.83 | — | -3.49 | -24.86 | 1.83 | 0.00% | — | — | -54.42% | -49.69% | -26.72% | 0.08 | -107.89 | 0.56 | 0.08 | 0.01 | 1333.00% | — | -444673.00% | -6.69% | -0.11 | -11.60% | 0.00% | 0.00% | 4.78% | -3.48 | -14.92 | — | -1.04 |
| INO | Inovio Pharmaceuticals, I… | $1.81 | 97M | +981% | -57% | — | +13,527% | -0.49 | 0.77 | 243.22 | 0.28 | — | 0.77 | 100.00% | -51616.91% | -49254.27% | -115.42% | 1958.18% | -75.49% | 0.17 | -632.05 | 2.77 | 2.70 | 0.52 | -3514.00% | -7383.00% | -1614.00% | -197.43% | -2.95 | 1821.69% | 0.00% | 0.00% | 131.88% | 0.26 | 0.28 | -134.48 | -23.30 |
| IRD | Opus Genetics, Inc. | $4.16 | 286.89M | +1,572% | -90% | — | +1,569% | -0.46 | 3.97 | 2.43 | 0.06 | -0.13 | 3.97 | 100.00% | -564.72% | -523.40% | -203.19% | 512.82% | -126.71% | 0.00 | — | 3.24 | 3.20 | 0.53 | 36739.00% | -4230.00% | 220000.00% | -95.73% | -2.26 | 211.29% | 0.00% | 0.00% | 0.30% | 0.06 | 0.14 | -0.33 | -9.18 |
| IXHL | Incannex Healthcare Limit… | $4.24 | 48.7M | +3,609% | +49% | — | — | -0.39 | 1.35 | 210.33 | -0.07 | -0.04 | 1.35 | 100.00% | -27661.63% | -54517.44% | -381.09% | -1055.21% | -250.09% | 0.02 | -78.51 | 2.86 | 2.82 | 0.31 | 109298.00% | 37870.00% | -2234.00% | -69.22% | -1.79 | -577.00% | 0.00% | 0.00% | 51.39% | -0.14 | -0.26 | 38.46 | -12.32 |
| LUCD | Lucid Diagnostics Inc. | $1.44 | 146.54M | +85,309% | -60% | — | — | -1.54 | 13.02 | 16.16 | -1.56 | — | 15.08 | -90.20% | -1059.64% | -1047.61% | -2956.43% | 5531.77% | -157.04% | 3.94 | -1771.23 | 1.07 | 0.97 | 0.02 | -1667.00% | 7900.00% | 3556.00% | -63.78% | -1.88 | 5379.70% | 0.00% | 0.00% | 0.00% | -1.50 | -1.54 | 15.90 | -12.37 |
| SEER | Seer, Inc. | $1.72 | 96.75M | +1,276% | +24% | — | — | -1.41 | 0.37 | 8.76 | 0.94 | -47.63 | 0.37 | 48.99% | -717.72% | -620.91% | -23.91% | -88.56% | -21.57% | 0.08 | — | 16.53 | 15.83 | 0.16 | 296.00% | -813.00% | -2513.00% | -40.66% | -3.01 | -43.96% | 0.00% | 0.00% | 18.30% | 0.88 | 1.78 | -6.33 | 0.30 |
| VTGN | VistaGen Therapeutics, In… | $0.59 | 19.2M | +3,740% | +110% | — | +12,444% | -1.41 | 1.03 | 149.14 | 0.12 | -14.28 | 1.03 | 100.00% | -11517.08% | -10579.84% | -55.68% | 986.92% | -49.44% | 0.02 | — | 6.51 | 6.38 | 1.19 | 987.00% | -5432.00% | 6344.00% | -58.34% | -3.34 | 745.62% | 0.00% | 0.00% | 0.00% | 0.12 | 0.15 | -13.36 | -4.85 |
About Scilex Holding Company
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
- CEO
- Henry H. Ji
- Employees
- 115
- Beta
- 1.37
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($4.86 ÷ $10.58) − 1 = -54.06% (DCF, example).